Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITADEL-203 phase 2 study of parsaclisib in relapsed or refractory follicular lymphoma
MOH_2018-06-07_001898Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of parsaclisib in follicular lymphoma (FL) (2 arms), sponsored by Incyte. Primary endpoint: Efficacy. Started Apr 2018; status: active, not recruiting.
02
Drugs
parsaclisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on MOH_2018-06-07_001898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-07_001898.